Profile data is unavailable for this security.
About the company
Amneal Pharmaceuticals, Inc., is a fully integrated global essential medicine company. The Company is engaged in the development, manufacturing, and distribution of a diverse portfolio of approximately 270 pharmaceutical products, primarily within the United States. The Company’s Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermal across a broad range of therapeutic categories. The Company's Specialty segment’s portfolio includes central nervous system disorders (Parkinson’s disease, spasticity, migraine), endocrinology (hypothyroidism), and other therapeutic areas. The Company’s AvKARE segment provides pharmaceuticals, medical and surgical products, and services to government, retail, and institutional markets.
- Revenue in USD (TTM)2.50bn
- Net income in USD-168.69m
- Incorporated2023
- Employees7.70k
- LocationAmneal Pharmaceuticals Inc400 Crossing Boulevard, 3rd FloorBRIDGEWATER 08807United StatesUSA
- Websitehttps://amneal.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Agios Pharmaceuticals Inc | 29.40m | -352.62m | 1.94bn | 383.00 | -- | 2.60 | -- | 65.92 | -6.31 | -6.31 | 0.5257 | 13.11 | 0.0294 | 0.1715 | 11.24 | 76,770.23 | -35.24 | -29.54 | -37.04 | -31.88 | 89.95 | -- | -1,199.26 | -3,826.10 | 12.39 | -- | 0.00 | -- | 88.36 | -22.25 | -51.89 | -- | -32.23 | -- |
| Catalyst Pharmaceuticals Inc | 411.35m | 65.12m | 1.95bn | 167.00 | 30.63 | 3.47 | 19.30 | 4.73 | 0.5384 | 0.5384 | 3.60 | 4.76 | 0.7806 | 3.60 | 8.76 | 2,463,156.00 | 12.36 | 25.42 | 14.19 | 29.81 | 86.74 | 85.63 | 15.83 | 30.87 | 4.83 | -- | 0.00 | 0.00 | 85.90 | 280.39 | -14.05 | -- | 20.21 | -- |
| Beam Therapeutics Inc | 360.91m | -134.74m | 1.96bn | 436.00 | -- | 2.14 | -- | 5.43 | -1.74 | -1.74 | 4.54 | 11.10 | 0.2681 | -- | -- | 827,777.50 | -10.01 | -24.54 | -11.79 | -29.26 | -- | -- | -37.33 | -211.96 | -- | -- | 0.00 | -- | 520.01 | -- | 54.16 | -- | 20.78 | -- |
| Amphastar Pharmaceuticals Inc | 676.21m | 154.69m | 2.02bn | 1.76k | 14.23 | 3.00 | 10.04 | 2.98 | 2.90 | 2.90 | 12.70 | 13.77 | 0.576 | 2.79 | 5.66 | 383,991.50 | 13.33 | 9.42 | 15.75 | 11.56 | 54.73 | 47.83 | 23.14 | 15.23 | 1.72 | 8.48 | 0.4692 | 0.00 | 29.14 | 16.94 | 50.51 | -- | -4.00 | -- |
| Amneal Pharmaceuticals Inc | 2.50bn | -168.69m | 2.11bn | 7.70k | -- | -- | 19.86 | 0.8473 | -0.5642 | -0.5642 | 11.52 | -0.1381 | 0.7046 | 2.94 | 4.11 | 324,059.50 | -3.40 | -4.80 | -4.27 | -5.93 | 35.28 | 34.76 | -4.82 | -9.00 | 0.97 | 0.8617 | 1.01 | -- | 8.20 | 7.56 | 35.38 | -- | -6.55 | -- |
| Rocket Pharmaceuticals Inc | 0.00 | -249.31m | 2.12bn | 268.00 | -- | 4.80 | -- | -- | -2.87 | -2.87 | 0.00 | 4.87 | 0.00 | -- | -- | 0.00 | -49.16 | -35.26 | -52.49 | -37.49 | -- | -- | -- | -- | -- | -- | 0.0458 | -- | -- | -- | -10.70 | -- | 62.52 | -- |
| ADMA Biologics Inc | 283.18m | -3.64m | 2.12bn | 624.00 | -- | 13.81 | 445.19 | 7.50 | -0.0204 | -0.0204 | 1.23 | 0.6632 | 0.8188 | 1.00 | 7.44 | 453,808.40 | -1.05 | -24.80 | -1.21 | -28.00 | 39.39 | 17.02 | -1.29 | -51.31 | 1.86 | 2.12 | 0.4598 | -- | 67.59 | 72.34 | 57.15 | -- | 18.91 | -- |
| Arvinas Inc | 71.30m | -354.80m | 2.14bn | 445.00 | -- | 3.51 | -- | 30.04 | -6.05 | -6.05 | 1.22 | 8.93 | 0.0597 | -- | 12.08 | 160,224.70 | -29.59 | -22.01 | -37.90 | -26.47 | -- | -- | -495.65 | -316.55 | -- | -- | 0.0012 | -- | -40.26 | 40.53 | -30.02 | -- | 0.4852 | -- |
| Kymera Therapeutics Inc | 79.41m | -154.59m | 2.15bn | 186.00 | -- | 3.03 | -- | 27.11 | -2.50 | -2.50 | 1.29 | 11.59 | 0.1072 | -- | 29.69 | 424,668.40 | -20.86 | -23.03 | -22.67 | -27.64 | -- | -- | -194.67 | -207.82 | -- | -- | 0.0032 | -- | 67.84 | -- | 5.07 | -- | 91.01 | -- |
| Geron Corp | 520.00k | -201.40m | 2.18bn | 141.00 | -- | 6.26 | -- | 4,197.55 | -0.3464 | -0.3464 | 0.0009 | 0.5876 | 0.0012 | -- | 0.3225 | 3,687.94 | -44.41 | -51.32 | -54.44 | -64.90 | -- | -- | -38,729.81 | -19,949.13 | -- | -- | 0.1935 | -- | -60.23 | -25.97 | -29.76 | -- | 120.29 | -- |
| Novocure Ltd | 525.66m | -192.74m | 2.19bn | 1.45k | -- | 6.08 | -- | 4.16 | -1.81 | -1.81 | 4.92 | 3.34 | 0.4579 | 3.57 | 7.51 | 361,774.90 | -16.79 | -7.74 | -19.40 | -8.95 | 74.82 | 77.22 | -36.67 | -14.69 | 5.99 | -- | 0.6132 | -- | -5.30 | 15.47 | -123.75 | -- | 32.19 | -- |
| Deciphera Pharmaceuticals Inc | 174.91m | -190.42m | 2.20bn | 355.00 | -- | 6.61 | -- | 12.58 | -2.21 | -2.21 | 2.03 | 3.85 | 0.3607 | 0.2287 | 6.35 | 492,704.20 | -39.26 | -44.54 | -47.45 | -52.24 | 96.95 | -- | -108.87 | -245.88 | 3.94 | -- | 0.00 | -- | 21.87 | -- | -8.95 | -- | -7.11 | -- |
| Vera Therapeutics Inc | 0.00 | -94.30m | 2.23bn | 55.00 | -- | 6.30 | -- | -- | -2.04 | -2.04 | 0.00 | 6.49 | 0.00 | -- | -- | 0.00 | -29.99 | -- | -31.92 | -- | -- | -- | -- | -- | -- | -- | 0.124 | -- | -- | -- | -7.79 | -- | -- | -- |
| Myriad Genetics, Inc. | 774.20m | -234.60m | 2.29bn | 2.70k | -- | 3.02 | -- | 2.96 | -2.82 | -2.82 | 9.11 | 8.40 | 0.6792 | 10.41 | 6.53 | 286,740.80 | -20.58 | -- | -23.57 | -- | 68.79 | -- | -30.30 | -- | 1.82 | -225.20 | 0.0485 | -- | 11.03 | -- | -135.09 | -- | -- | -- |
Data as of May 15 2024. Currency figures normalised to Amneal Pharmaceuticals Inc's reporting currency: US Dollar USD
17.65%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2024 | 13.53m | 4.38% |
| Rubric Capital Management LPas of 31 Mar 2024 | 9.54m | 3.09% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 8.23m | 2.67% |
| Citadel Advisors LLCas of 31 Dec 2023 | 6.50m | 2.11% |
| Neuberger Berman Investment Advisers LLCas of 31 Dec 2023 | 3.74m | 1.21% |
| Dimensional Fund Advisors LPas of 31 Mar 2024 | 3.64m | 1.18% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 2.80m | 0.91% |
| Geode Capital Management LLCas of 31 Dec 2023 | 2.44m | 0.79% |
| Nantahala Capital Management LLCas of 31 Dec 2023 | 2.33m | 0.76% |
| TIAA-CREF Investment Management LLCas of 31 Dec 2023 | 1.70m | 0.55% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
